Elusys picks up $50.2M BARDA funds to advance anthrax antitoxin
03:20 EDT 3 Aug 2012 | SCRIP
Elusys Therapeutics scored another $50.2 million under a broader contract with the US government to advance the development of the privately held firm's experimental inhalational anthrax antitoxin Anthim (ETI-204), a high-affinity.....
Original Article: Elusys picks up $50.2M BARDA funds to advance anthrax antitoxin
More From BioPortfolio on "Elusys picks up $50.2M BARDA funds to advance anthrax antitoxin"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
